<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6399">
  <stage>Registered</stage>
  <submitdate>2/03/2017</submitdate>
  <approvaldate>2/03/2017</approvaldate>
  <nctid>NCT03072238</nctid>
  <trial_identification>
    <studytitle>Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer</studytitle>
    <scientifictitle>A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer</scientifictitle>
    <utrn />
    <trialacronym>IPATential150</trialacronym>
    <secondaryid>CO39303</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metastatic Prostate Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Ipatasertib
Treatment: drugs - Abiraterone
Treatment: drugs - Placebo

Experimental: Ipatasertib + Abiraterone - Ipatasertib and abiraterone, administered orally, in 28-day cycles

Active Comparator: Placebo + Abiraterone - Placebo plus abiraterone, administered orally, in 28-day cycles


Treatment: drugs: Ipatasertib
Oral tablets, 400 mg, given once daily (QD) beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity

Treatment: drugs: Abiraterone
Oral tablets of abiraterone, 1000 mg QD, taken on an empty stomach and swallowed whole with water, plus prednisone/prednisolone, 5 mg twice daily (BID)

Treatment: drugs: Placebo
Oral tablets (matched to ipatasertib appearance), given QD beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Investigator-Assessed Radiographic Progression-Free Survival (rPFS) - Radiographic progression-free survival is defined as time from date of randomization to the first occurrence of documented disease progression, as assessed by the investigator with use of the Prostate Cancer Working Group 3 (PCWG3) criteria or death from any cause, whichever occurs first. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; and an absolute increase of at least 5 mm in the sum of diameters of target lesions; and the appearance of one or more new lesions. rPFS will be analyzed in participants with phosphatase and tensin homolog (PTEN)-loss tumors (using the Ventana PTEN immunohistochemistry (IHC) assay) and evaluated against the intent-to-treat (ITT) population.</outcome>
      <timepoint>Up to approximately 31 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Pain Progression - Pain severity progression refers to pain onset for participants who are asymptomatic at baseline or pain worsening for those who are mildly symptomatic at baseline. Pain severity will be graded on a 10-point scale, with 0=no pain and 10=severe pain. Pain severity progression is defined as a = 2-point absolute increase from baseline.</outcome>
      <timepoint>Up to approximately 65 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Initiation of Cytotoxic Chemotherapy - Time to initiation of cytotoxic chemotherapy is defined as the time interval from the date of randomization to the date of initiation of cytotoxic chemotherapy (use of antineoplastic agents: docetaxel, cabazitaxel, mitoxantrone, estramustine, cisplatin, carboplatin, cyclophosphamide, doxorubicin, mitomycin, irinotecan, 5-fluorouracil, gemcitabine, or etoposide) for prostate cancer.</outcome>
      <timepoint>Up to approximately 65 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival - Overall Survival (OS) will be measured from randomization to the time of death due to any cause.</outcome>
      <timepoint>Up to approximately 65 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Function Deterioration - Time to function deterioration is defined as the time interval from the date of randomization to the date of a decrease of 10-point or more on either the 0-100 physical function (PF) or the role functioning (RF) scores from the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30).</outcome>
      <timepoint>Up to approximately 65 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Prostate-Specific Antigen (PSA) Progression - Time to PSA progression is defined as the time from the date of randomization to the first occurrence of PSA progression, per the PCWG3 criteria. PSA progression is defined as = 25% relative increase of = 2 ng/mL above the baseline or the smallest sum on study, which is confirmed by a second consecutive value = 3 weeks later.</outcome>
      <timepoint>Up to approximately 65 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to First Opioid Use - Time to first opioid use is defined as the time interval from the date of randomization to the date of an initiation of opioid analgesic use for cancer-related pain, and consumption reported on at least 7 consecutive days.</outcome>
      <timepoint>Up to approximately 65 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Symptomatic Skeletal Event (SSE) - Time to first SSE is defined as the time interval from the date of randomization to the date of an SSE.</outcome>
      <timepoint>Up to approximately 65 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Objective Response Rate (ORR) - An objective response is defined per response evaluation criteria in solid tumors (RECIST) v1.1 and PCWG3 criteria. Participants without a post-baseline tumor assessment will be considered non-responders. ORR is defined as complete response (CR) or partial response (PR). Complete response (CR) is defined as disappearance of all target lesions. Partial response (PR) is defined as least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.</outcome>
      <timepoint>Up to approximately 65 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PSA Response Rate - PSA response rate is defined as the percentage of participants achieving a PSA decline =50% from baseline. Participants without a post-baseline PSA assessment will be considered non-responders.</outcome>
      <timepoint>Up to approximately 65 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Investigator-Assessed rPFS in Participants With PTEN-Loss Tumors by Next-Generation Sequencing (NGS) - Investigator-assessed rPFS (time from date of randomization to the first occurrence of documented disease progression) per PCWG3 criteria will be analyzed in participants with PTEN-loss tumors by NGS. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; and an absolute increase of at least 5 mm in the sum of diameters of target lesions; and the appearance of one or more new lesions.</outcome>
      <timepoint>Up to approximately 65 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Eastern Collaborative Oncology Group (ECOG) performance status of 0 or 1 at screening

          -  Adequate hematologic and organ function within 28 days before the first study
             treatment

          -  Ability to comply with the study protocol, in the investigator's judgment

          -  Willingness and ability of participants (or observers, caregivers) to use the
             electronic device to report selected study outcomes

          -  Life expectancy of at least 6 months

          -  Agreement to remain abstinent (refrain from heterosexual intercourse) or use
             contraceptive measures, and agreement to refrain from donating sperm

          -  For enrollment into the China extension cohort, residence in the People's Republic of
             China

        Disease-specific 

          -  Histologically confirmed prostate adenocarcinoma without neuroendocrine
             differentiation or small-cell features

          -  Consent to provide a formalin-fixed paraffin-embedded (FFPE) tissue block (preferred)
             or a minimum of 15 (20 preferred) freshly cut unstained tumor slides from the most
             recently collected, available tumor tissue accompanied by an associated pathology
             report (with tumor content information, Gleason score, and disease staging) for PTEN
             IHC and NGS testing and for other protocol-mandated secondary and exploratory
             assessments. Cytologic or fine-needle aspiration samples are not acceptable. Tumor
             tissue from bone metastases that is subject to decalcification is not acceptable.

          -  A valid PTEN IHC result (per central testing) (e.g., participants with an "invalid" or
             "failed" PTEN IHC result are not permitted to enroll)

          -  Metastatic disease documented prior to randomization by bone lesions on bone scan or
             soft tissue disease by computed tomography (CT) or magnetic resonance imaging (MRI)

          -  Asymptomatic or mildly symptomatic form of prostate cancer

          -  Progressive disease before initiating study treatment

          -  Ongoing androgen deprivation with gonadotropin-releasing hormone (GnRH) analog or
             bilateral orchiectomy, with serum testosterone &lt; 50 ng/dL (&lt; 2.0 nmol/L) within 28
             days before randomization</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Inability or unwillingness to swallow whole pills

          -  History of malabsorption syndrome or other condition that would interfere with enteral
             absorption

          -  Clinically significant history of liver disease consistent with Child-Pugh Class B or
             C, including cirrhosis, current alcohol abuse, or current known active infection with
             hepatitis B virus (HBV) or hepatitis C virus (HCV)

          -  Need for current chronic corticosteroid therapy (&gt; 10 mg/day of prednisone or an
             equivalent dose of other anti-inflammatory corticosteroids)

          -  Active infection requiring intravenous (IV) antibiotics within 14 days before Day 1,
             Cycle 1

          -  Immunocompromised status because of current known active infection with HIV or because
             of the use of immunosuppressive therapies for other conditions

          -  Major surgical procedure or significant traumatic injury within 28 days prior to Day
             1, Cycle 1, or anticipation of the need for major surgery during study treatment

          -  History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias, such
             as structural heart disease (e.g., severe left ventricular systolic dysfunction, left
             ventricular hypertrophy), coronary heart disease (symptomatic or with ischemia
             demonstrated by diagnostic testing), myocardial infarction or atrial thrombotic events
             within the past 6 months, severe unstable angina, New York Heart Association Class III
             and IV heart disease or depressed left ventricular ejection fraction (LVEF; &lt; 50%),
             clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia,
             hypocalcemia), or family history of sudden unexplained death or long QT syndrome

          -  Current treatment with medications that are well known to prolong the QT interval

          -  History of other malignancy within the previous 5 years, except for appropriately
             treated non-melanoma skin carcinoma, or participants who have undergone potentially
             curative therapy with no evidence of disease and are deemed by the treating physician
             to be at low risk for recurrence

          -  Any other diseases, cardiovascular, pulmonary, or metabolic dysfunction, physical
             examination finding, or clinical laboratory finding giving reasonable suspicion of a
             disease or condition that contraindicates the use of an investigational drug or that
             may affect the interpretation of the results or renders the participants at high risk
             from treatment complications.

        Disease-Specific 

          -  Pathologic findings consistent with small-cell or neuroendocrine carcinoma of the
             prostate

          -  Treatment with chemotherapy for the treatment of castration-resistant prostate cancer

          -  Use of opiate analgesics for cancer-related pain, including codeine and
             dextropropoxyphene, currently or any time within 4 weeks of Day 1, Cycle 1

          -  Any prior anti-cancer therapy

          -  Known untreated or active central nervous system (CNS) metastases (progressing or
             requiring anticonvulsant medications or corticosteroids for symptomatic control); a CT
             or MRI scan of the brain will be performed at screening if required by the local
             health authority

          -  Any chronic therapy or use of food supplements that are strong CYP3A4/5 inducers or
             sensitive CYP2D6 substrates with a narrow therapeutic window

        Abiraterone-Specific 

          -  Uncontrolled hypertension (systolic blood pressure = 160 mmHg or diastolic blood
             pressure = 95 mmHg)

          -  History of pituitary or adrenal dysfunction

          -  Atrial fibrillation or other cardiac arrhythmia requiring therapy

        Ipatasertib-Specific 

          -  Type 1 or Type 2 diabetes mellitus requiring insulin at study entry

          -  History of inflammatory bowel disease (e.g., Crohn disease and ulcerative colitis),
             active bowel inflammation (e.g., diverticulitis)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>30/06/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>850</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>24/08/2023</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC</recruitmentstate>
    <hospital>Macquarie University Hospital - Macquarie University</hospital>
    <hospital>Adelaide Cancer Centre - Kurralta Park</hospital>
    <hospital>Monash Medical Centre; Oncology - East Bentleigh</hospital>
    <hospital>Peter Maccallum Cancer Centre - Melbourne</hospital>
    <hospital>Eastern Health; GU - Oncology - Melbourne</hospital>
    <postcode>2109 - Macquarie University</postcode>
    <postcode>5037 - Kurralta Park</postcode>
    <postcode>VIC 3165 - East Bentleigh</postcode>
    <postcode>3000 - Melbourne</postcode>
    <postcode>3128 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Graz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Linz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Salzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Kortrijk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liège</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>MG</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>RN</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>RS</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>SP</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Costa Rica</country>
      <state>San Jose</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Aarhus N</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Odense</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Angers</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Caen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clermont Ferrand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Colmar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>La Roche Sur Yon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nimes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Poitiers</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Reims CEDEX</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint-Mande</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Suresnes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre-Les-Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Muenster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Reutlingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Tübingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Weiden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Patras</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Thessaloniki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Miskolc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Cork</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Beer Sheva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Kfar-Saba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petach Tikva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ramat Gan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Campania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Emilia-Romagna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lazio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Toscana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Trentino-Alto Adige</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Aichi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Aomori</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Chiba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Gunma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hokkaido</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Ishikawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kanagawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kochi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kumamoto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kyoto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Niigata</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Osaka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Yamaguchi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeonggi-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico City (federal District)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Sinaloa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Yucatan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Durango</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Grålum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Lørenskog</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Opole</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Coimbra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisboa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moskovskaja Oblast</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Barnaul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Nizhny Novgorod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovenia</country>
      <state>Ljubljana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Islas Baleares</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Navarra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cordoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Malaga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Salamanca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taoyuan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Chiangmai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Blackburn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leicester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Middlesborough</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Northwood</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sutton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Wolverhampton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of
      ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus
      abiraterone and prednisone/prednisolone in participants with metastatic castrate-resistant
      prostate cancer (mCRPC).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03072238</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Reference Study ID Number: CO39303 www.roche.com/about_roche/roche_worldwide.htm</name>
      <address />
      <phone>888-662-6728 (U.S.Only)</phone>
      <fax />
      <email>global-roche-genentech-trials@gene.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>